ArticleExploration (Beijing, China)2026
Silencing SGO2 by Oxamic Acid Dissociates Glycolysis and BRCA1-Mediated DNA Repair to Improve the Chemosensitivity of Lung Adenocarcinoma.
Article in Exploration (Beijing, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aerobic glycolysis and DNA damage repair participate in modulating LUAD chemo sensitivity, while the connection between glycolysis and DNA repair is not fully discovered. Here, integrated multi-omics analyses recognized SGO2 as a glycolysis- and DNA repair-associated gene. SGO2 was up regulated in lung adenocarcinoma (LUAD) compared to normal controls and independently predicted poor prognosis in LUAD patients in three independent cohorts. In addition, SGO2 compromised the cisplatin (CDDP) sensitivity of LUAD in vitro and in vivo. Mechanistically, SGO2 interacted with BRCA1 to restrain BRCA1 ubiquitination and degradation, thereby enhancing homologous recombination repair signaling. Interestingly, a dietary bioactive compound, oxamic acid (OA) served as a glycolysis inhibitor to attenuate lactate (LA) production, thereby impairing histone H3 lysine 18 lactylation (H3K18la) and histone H3 lysine 27 acetylation (H3K27ac)-mediated chromatin accessibility to suppress SGO2 transcription. Furthermore, OA repressed SGO2/BRCA1-regulated homologous recombination repair signaling to mitigate LUAD progression and was presented as a therapeutic compound with no apparent toxicity in vivo. This study demonstrated that SGO2 is a downstream effector of glycolysis and an upstream regulator of DNA damage repair. Silencing SGO2 with OA improved LUAD chemo sensitivity. Our work highlights the potential of SGO2 as a target for therapeutic intervention and OA as a food-bioactive compound for LUAD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.